The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer.

The increasing use of bacillus Calmette-Guerin in the treatment of patients with low stage bladder cancer will inevitably bring attention to problems of proper use and toxicity. There is a need to identify patients who are most likely to benefit from this therapy and those who may be at risk for serious complications.